What I see too often is organisations treating metabolic risk as a wellbeing issue when it is already a balance sheet issue.
By the time obesity, hypertension, dyslipidaemia and insulin resistance show up in claims data, the cost signal is already well established. The workforce impact is visible in absence, productivity drag and rising chronic disease burden. The insurance impact follows quickly behind. In 2023–2024, 64.5% of adults aged 18 and over in England were overweight or living with obesity, up from 61.2% in 2015–2016. That trend does not stop at the office door. It is now embedded in workforce health risk and, in my view, it is one of the clearest leading indicators of future employer health cost inflation. Without intervention, group health insurance premiums for mid-to-large organisations could rise by 15–20% over the next five years as claims linked to metabolic risk continue to escalate.
The Rising Tide of Metabolic Risks in UK Workforces
The problem is no longer theoretical. Employee health risk is worsening, and it is already showing up in corporate cost structures.
CIPD’s 2025 Health and Wellbeing at Work survey found average sickness absence had reached 9.4 days per employee, the highest level on record, and 62% above pre-pandemic levels. A meaningful share of that burden is tied to the long-tail impact of metabolic-driven illness, particularly type 2 diabetes and cardiovascular disease. ONS data for 2025 adds further weight: 148.8 million working days were lost to sickness or injury, equivalent to 4.4 days per worker, with minor illness and musculoskeletal conditions among the biggest drivers - both frequently compounded by underlying metabolic dysfunction.
This matters because insurers are not waiting for employers to catch up. They are already repricing risk.
Mercer Marsh Benefits’ 2025 Health Trends research identifies metabolic and cardiovascular risks as the leading driver of medical cost growth globally. At the same time, 82% of insurers report a rise in cancer claims among under-50s, often associated with earlier metabolic damage. In the UK, HSE places the annual cost of workplace ill health at £22.9 billion in 2023/24, with £16.4 billion linked to chronic conditions that are, at least in part, addressable through earlier metabolic screening and intervention. That is not simply a clinical concern. It is a direct cost pressure on group premiums, reserves and long-term risk exposure.
Defining Metabolic Risk and Its Workforce Footprint
Metabolic risk is not one condition. It is a cluster of predictable, measurable risk factors that tend to travel together and become expensive when ignored.
Metabolic syndrome, which is typically characterised by abdominal obesity, elevated blood pressure, raised blood glucose and abnormal cholesterol, now affects more than one in three UK adults based on 2025 estimates drawn from NHS Health Survey trends. In working populations, prevalence rises sharply with age, reaching 45% in the 40–59 age bracket. For most mid-to-large employers, that is the core of the workforce and much of the leadership population. This is not peripheral risk. It sits in the middle of the employee base.
The exposure is not confined to traditionally high-risk sectors either. BMJ Open found obesity prevalence among healthcare workers at 25.1%, above the general population benchmark, which points to something broader and more systemic across professional cohorts.
Swiss Re’s 2023 analysis links poor metabolic health to more than 74% of global non-communicable disease deaths, with insulin resistance acting as a major accelerator. For employers, this translates into slower productivity, higher utilisation and greater claims intensity. Nesta’s 2025 analysis estimates obesity and excess weight already cost the UK £30.8 billion a year in lost productivity, with that figure projected to rise to £36 billion by 2035 if left unchecked. I have reviewed enough insurer and reinsurer risk models to be clear on one point: metabolic markers are no longer peripheral underwriting inputs. They are increasingly central to how future costs are being priced.
Data Sources for Forecasting Insurance Trajectories
The data already exists. Most organisations simply are not using it properly.
The strongest signals sit across three places: wearable integrations, occupational health screening and aggregated claims history. NHS Digital and ONS data from the Health Survey for England 2024 provide a credible baseline for obesity, hypertension and diabetes prevalence. From there, employers can build forward-looking projections using biomarkers such as HbA1c and waist-to-height ratio, both of which Mercer identifies as strong predictors of future claims, with forecasting accuracy in the 80–90% range.
The practical question is not whether organisations have enough data. It is whether they are correlating it properly.
A sensible starting point is to benchmark internal workforce health data against population baselines, including 26.5% adult obesity in 2023–2024, then model variance by age, risk tier, and claims history. Swiss Re has already made the underwriting case for metabolic scoring as a means of identifying reversible risk earlier and stabilising portfolios over time. In practice, the most useful approach is to correlate employee health app and screening data against prior claims experience, then model likely cost trajectories over a three-to-five-year horizon. That approach has already been validated in Deloitte-style simulations showing 10–15% premium savings when targeted intervention is applied early.
Quantifying the Insurance Cost Imperative
Metabolic risk does not increase employer costs incrementally. It compounds it.
That compounding effect is already visible in insurance pricing. HSE’s £16.4 billion chronic ill-health burden feeds directly into employer health exposure. Mercer’s 2025 findings place metabolic risk at the top of insurer cost concerns, helping drive the double-digit premium increases now showing up across the market. More broadly, obesity alone costs the UK £126 billion annually, including £12.6 billion in NHS treatment costs, with much of that economic burden ultimately recycled back to employers through higher healthcare costs, insurance pricing and lost productivity.
For a 5,000-employee organisation, a 5% rise in metabolic risk prevalence could add between £500,000 and £1 million in annual premium costs, based on Gallagher trend analysis adjusted for UK market conditions. That is precisely why relying on retrospective claims review is no longer enough. If Finance is only seeing this at renewal, it is already too late.
Implications for Leadership Teams
This is where the issue stops being an HR programme and becomes an executive responsibility.
HR teams are already managing the consequences in absence, retention and workforce resilience. HSE reported 964,000 work-related stress cases in 2024/25, with metabolic health often acting as an aggravating factor in both physical and psychological strain. Finance teams are carrying the downstream exposure through higher claims volatility and self-insured losses. Risk leaders, under growing regulatory scrutiny and FCA expectations, should already be stress-testing health portfolios against rising non-communicable disease exposure.
These are not separate issues. They are the same risk showing up in different lines of accountability.
Left unmanaged, metabolic risk erodes margin, increases insurance cost, weakens productivity and signals poor stewardship to investors and stakeholders alike.
Strategic Steps for C-Suite Implementation
Commission baseline metabolic audits through occupational health partners, focusing on BMI, blood pressure and glycaemic markers in employees over 40, then benchmark findings against ONS and NHS baselines.
Integrate wearable, screening and EHR data into insurer and actuarial models with partners such as BUPA or AXA to forecast premium exposure over the next three to five years using metabolic risk indices aligned to Swiss Re methodologies.
Pilot incentive-linked intervention programmes focused on high-risk cohorts first. KPMG’s evidence suggests a $3 return for every $1 invested through lower claims and reduced absenteeism.
Build metabolic KPIs into HR and risk dashboards and assign executive accountability for movement, rather than leaving this buried in benefits reporting.
Work directly with insurers and reinsurers on transparent underwriting models that reward earlier intervention and better data visibility, with potential premium credits of 10–15% based on Mercer benchmarks.
Looking Ahead
The organisations that manage this well will not be the ones with the best wellbeing messaging. They will be the ones using metabolic risk data early enough to change cost trajectories before insurers do it for them.
The evidence is already clear. The claims signal is already visible. The pricing response is already underway.
Audit the risk, model the exposure and act before the next renewal cycle turns a preventable health problem into a permanent cost line.